Electrophysiology & Arrhythmia

The need for permanent pacemakers in patients with severe aortic stenosis who undergo transcatheter aortic valve replacement (TAVR) remains a complication, even as TAVR expands into lower-risk groups. That may prove to be a limitation, especially with younger patients who may have decades of life ahead of them.

After adjusting for sociodemographics, health behaviors and clinical characteristics, patients with atrial fibrillation who had low health literacy were less likely to be aware of their diagnosis, according to an analysis of members from two large health insurance companies.

A meta-analysis of four randomized trials found that using primary prevention implantable cardioverter defibrillators (ICDs) decreased all-cause mortality by 25 percent in patients with nonischemic cardiomyopathy.

Although research has shown automated external defibrillators (AEDs) can increase survival after cardiac arrest, only 17 of 50 U.S. states required at least some of their schools install AEDs as of February 2016, according to a database analysis.

Phillips recalled the HeartStart MRx monitor/defibrillator after discovering electrical and battery connection issues that could prevent the device from powering up, charging and delivering an electrical shock therapy.

Patients with atrial fibrillation and at least one additional risk factor for stroke who received digoxin had higher mortality rates compared with those who did not take digoxin, according to an analysis of a randomized trial.

Nearly 85 percent of patients with a history of atrial fibrillation who had an acute ischemic stroke did not receive guideline-recommended anticoagulation or had anticoagulation levels that did not fall in the therapeutic range, according to a registry analysis.

The U.S. Food and Drug Administration (FDA) approvead Medtronic’s Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection, designed to accurately identify abnormal heartbeats.

CMS has approved coverage of Medtronic’s Micra transcatheter pacing system for patients who need a single-chamber pacemaker.

The FDA granted premarket approval to Zoll Corporation’s hospital wearable defibrillator.

Between 1999 and 2013, the adjusted rates of hospitalization for atrial fibrillation increased nearly 1 percent year per year among Medicare fee-for-service beneficiaries, while the median Medicare inpatient expenditure per beneficiary increased from $2,932 to $4,719 per stay.

Women who were healthy at baseline had an increased risk of atrial fibrillation if they had multiple pregnancies, according to an analysis of a large cohort.